Literature DB >> 9378970

Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells.

B J Czerniecki1, C Carter, L Rivoltini, G K Koski, H I Kim, D E Weng, J G Roros, Y M Hijazi, S Xu, S A Rosenberg, P A Cohen.   

Abstract

Human peripheral blood contains a small subpopulation of immature dendritic cells (iDC) distinguished from circulating monocytes by their low expression of CD14. We utilized leukapheresis and countercurrent centrifugal elutriation to obtain myeloid origin mononuclear cell (MOMC) fractions of monocytes and iDC for study. These subpopulations were ultrastructurally and immunophenotypically similar before culture. After a 20- to 96-h culture either alone, with recombinant human granulocyte-monocyte CSF, or with endotoxin, greater up-regulation of costimulatory molecule expression was observed among iDC than among monocytes, and only iDC expressed the activation molecule CD83. Treatment with rhIL-4 caused many MOMC to develop morphologic properties of dendritic cells within 96 h, but costimulatory molecule up-regulation and CD14 down-regulation were heterogeneous, and CD83 expression was infrequent. In contrast, calcium ionophore (CI) treatment induced rapid and consistent effects in MOMC from both healthy volunteers and cancer patients, including down-regulated CD14 expression, acquisition of dendritic cell morphologic properties, up-regulated MHC and costimulatory molecule expression, and de novo CD83 expression. Many such effects occurred within 20 h of treatment. CI treatment activated purified CD14+ monocytes and also enhanced the spontaneous activation of purified CD14-/dim iDC in culture. Unfractionated MOMC, purified monocytes, and purified iDC displayed equivalently enhanced T cell-sensitizing efficiency following CI treatment. CD4+ T cell sensitization to keyhole limpet hemocyanin and CD8+ T cell sensitization to MART-1 melanoma-associated peptide were achieved in a single culture stimulation. Therefore, circulating monocytes and iDC can be induced by CI to manifest properties of activated DC, providing large numbers of efficient, nontransformed autologous APC for T cell sensitization strategies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9378970

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

Review 1.  Immunodeficiency due to defects in store-operated calcium entry.

Authors:  Stefan Feske
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

2.  Frequent calcium oscillations lead to NFAT activation in human immature dendritic cells.

Authors:  Mirko Vukcevic; Francesco Zorzato; Giulio Spagnoli; Susan Treves
Journal:  J Biol Chem       Date:  2010-03-26       Impact factor: 5.157

3.  Store-operated Ca²+ signaling in dendritic cells occurs independently of STIM1.

Authors:  Bidhan C Bandyopadhyay; Sandeep C Pingle; Gerard P Ahern
Journal:  J Leukoc Biol       Date:  2010-10-22       Impact factor: 4.962

Review 4.  Dendritic cells in melanoma immunotherapy.

Authors:  Mark B Faries; Brian J Czerniecki
Journal:  Curr Treat Options Oncol       Date:  2005-05

5.  Dendritic cell maturation and chemotaxis is regulated by TRPM2-mediated lysosomal Ca2+ release.

Authors:  Adriana Sumoza-Toledo; Ingo Lange; Hanna Cortado; Harivadan Bhagat; Yasuo Mori; Andrea Fleig; Reinhold Penner; Santiago Partida-Sánchez
Journal:  FASEB J       Date:  2011-07-13       Impact factor: 5.191

Review 6.  The regulation of dendritic cell function by calcium-signaling and its inhibition by microbial pathogens.

Authors:  S F Connolly; D J Kusner
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

7.  Rev-dependent indicator T cell line.

Authors:  Yuntao Wu; Margaret H Beddall; Jon W Marsh
Journal:  Curr HIV Res       Date:  2007-07       Impact factor: 1.581

8.  A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.

Authors:  Crystal L Mackall; Eunice H Rhee; Elizabeth J Read; Hanh M Khuu; Susan F Leitman; Donna Bernstein; Merertu Tesso; Lauren M Long; David Grindler; Margret Merino; William Kopp; Maria Tsokos; Jay A Berzofsky; Lee J Helman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 9.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

10.  Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.

Authors:  Sébastien Anguille; Evelien L J M Smits; Nathalie Cools; Herman Goossens; Zwi N Berneman; Vigor F I Van Tendeloo
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.